Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Cara Therapeutics ( (CARA) ) just unveiled an update.
On December 17, 2024, Cara Therapeutics entered into a merger agreement with Tvardi Therapeutics, where Tvardi will become a wholly-owned subsidiary of Cara. This strategic merger aims to advance the development of Tvardi’s therapies for fibrosis-driven diseases and is expected to close in the first half of 2025. The combined entity will be renamed Tvardi Therapeutics, Inc., and will trade under the Nasdaq symbol TVRD. The merger is anticipated to enhance the company’s market positioning by focusing on unmet needs in treating diseases like idiopathic pulmonary fibrosis and hepatocellular carcinoma, with expected clinical trial data in the second half of 2025.
More about Cara Therapeutics
Cara Therapeutics is a biopharmaceutical company that focuses on developing therapies for treating chronic pain and pruritus. The company is merging with Tvardi Therapeutics, which specializes in developing oral, small molecule therapies for fibrosis-driven diseases.
YTD Price Performance: -13.25%
Average Trading Volume: 150,006
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.26M
Find detailed analytics on CARA stock on TipRanks’ Stock Analysis page.
